A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With FGFR 1, 2, 3, or 4 Genetic Alterations
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs PRN 1371 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Principia Biopharma
- 03 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 03 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2018.
- 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.